[contact-form-7 id="15592" title="Tell me more"]

Contact Next Edge Capital

1 Toronto Street, Suite 200
Toronto, ON M5C 2V6

Telephone: 416.775.3600
Toll-free: 1.877.860.1080
Fax: 416.775.3601
Email: info@nextedgecapital.com

Next Edge Biotech and Life Sciences Opportunities Fund

Next Edge Biotech and Life Sciences Opportunities Fund



The Next Edge Biotech and Life Sciences Opportunities Fund (the ‘Fund’) seeks short and long-term capital appreciation through the ownership of biotechnology and life sciences companies. Investments by the Fund may be made globally.


Investing in companies of the future

A unique, well-defined process of investing in biotechnology and life sciences companies.

Why Invest in Biotech and Life Sciences?

  • Accelerated discoveries, as technology has fused with biotech.
  • Higher Success Rates on discoveries due to innovation from research and development progress.
  • Vast Wealth Creation potential due to rapidly increasing breakthroughs from the companies of tomorrow.
  • Accommodating regulatory environment.
  • Life Saving and Quality of Life Solutions are being created for all humankind by investing in the sector.

Why Invest in the Next Edge Biotech and Life Sciences Opportunities Fund?

  • Access to companies that have the potential to be tomorrow’s winners
  • Experienced management team with over two decades of experience in biotech and life sciences
  • A unique, well-defined investment process of investing in companies in this sector
  • Specialized knowledge and experience required to navigate and invest in this space
  • The Fund’s Portfolio Manager has a robust prior track record via other funds managed in biotech and healthcare
  • The Fund’s Portfolio Management team have a vast network of contacts within investible companies, key opinion leaders (KOL), research firms, and other information sources globally
  • Only dedicated fund in Canada with exposure to predominately small and midcap Biotech and Life Sciences companies


Portfolio Manager

Eden Rahim is the Portfolio Manager for the Next Edge Biotech and Life Sciences Opportunities Fund. Eden’s broad experience includes over twenty-five years as a Portfolio and Hedge Fund Money Manager, Options Strategist, Derivatives & Biotech Analyst.

Eden possesses a top quartile 5-year 5-Star growth fund Portfolio Manager track record on over $1 billion in assets across 4 mandates at RBC Global Asset Management, in addition, Eden has delivered a +26% compounded annual return across a biotechnology mandate between 1995-2003. His experience also includes overseeing 14 Covered Call ETFs (over $0.7 Billion AUM) in Canada, the US & Australia while at Horizons Exchange Traded Funds.

Eden is a regular guest speaker on the biotech industry on Bloomberg TV, BNN, as well as an author and contributor to many industry sources and major press articles in the US and Canada. He also contributes as a speaker at numerous healthcare conferences.


Associate Portfolio Manager

Michael Bird is the Associate Portfolio Manager and Trader for the Next Edge Biotech and Life Sciences Opportunities Fund. He possesses over twenty-five years of equity, options and derivative trading experience. Previously he was Vice President and Head of the equity derivatives group at Desjardins Securities. Other prior experience includes Vice President and Senior Trader in the equity derivatives group at RBC, Vice President at CIBC Wood Gundy, and options and proprietary trader at BNS. Mike has served on the TSE Derivative Markets Committee and is a former Director and Chair of the Audit Committee of Intrinsyc Technologies Corporation (TSX: ITC) in addition to other board experience.

Fund Type
Alternative Mutual Fund
Launch Date
December 2020
Minimum Initial Investment
CAD $5,000
Purchases / Redemptions
Management Fee
Class A
1% per annum; (1% Servicing Fee payable out of the Management Fee)
Class F
0% per annum
Performance Fees
20% of profits with a high water mark
Valuation Pricing
Fund Codes
Class A - NEC 216
Class F - NEC 217